Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 2:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Granulomatous Polyangiitis Clear all
Completed Phase 2 Interventional Results available

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

NCT01750697
View directory record Official record
Conditions
Granulomatosis With Polyangiitis
Interventions
Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
6
States / cities
Louisville, Kentucky • Hackensack, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 14, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

Rituximab Vasculitis Maintenance Study

NCT01697267
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
Interventions
Rituximab, Azathioprine
Biological · Drug
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Other
Eligibility
15 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Los Angeles, California • Ann Arbor, Michigan • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 14, 2026, 2:00 PM EDT
Completed Phase 2 Interventional

Steroids and Methotrexate to Treat Systemic Vasculitis

NCT00001256
View directory record Official record
Conditions
Inflammation, Vasculitis, Wegener's Granulomatosis
Interventions
prednisone and methotrexate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 14, 2026, 2:00 PM EDT
Completed Phase 1 Interventional

Diagnostic Effectiveness of Virtual Bronchoscopy

NCT00001515
View directory record Official record
Conditions
Bronchogenic Carcinoma, Chronic Granulomatous Disease, Job's Syndrome, Mycobacterium Infection, Wegener's Granulomatosis
Interventions
virtual bronchoscopy
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 14, 2026, 2:00 PM EDT
Completed Phase 1 Interventional

An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies

NCT00072592
View directory record Official record
Conditions
Wegener's Granulomatosis
Interventions
Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 14, 2026, 2:00 PM EDT
Completed No phase listed Observational

Educational Needs of Patients With Systemic Vasculitis

NCT02190929
View directory record Official record
Conditions
Behcet's Disease, Churg-Strauss Syndrome, Vasculitis, Central Nervous System, Giant Cell Arteritis, Wegener Granulomatosis, Henoch-Schoenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 14, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach

NCT01940094
View directory record Official record
Conditions
Granulomatosis With Polyangiitis
Interventions
5 mg Prednisone, 0 mg Prednisone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
7
States / cities
Kansas City, Kansas • Boston, Massachusetts • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 14, 2026, 2:00 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 14, 2026, 2:00 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Pediatric Vasculitis Initiative

NCT02006134
View directory record Official record
Conditions
Wegeners Granulomatosis (Granulomatosis With Polyangiitis), Microscopic Polyangiitis, Eosinophilic Granulomatosis With Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Primary CNS Vasculitis, Unclassified Vasculitis
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
Up to 20 Years
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2025
U.S. locations
10
States / cities
San Francisco, California • Gainesville, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 14, 2026, 2:00 PM EDT
Active, not recruiting Phase 1 Interventional

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

NCT06294236
View directory record Official record
Conditions
Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Interventions
SC291
Biological
Lead sponsor
Sana Biotechnology
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 14, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

NCT02020889
View directory record Official record
Conditions
Churg-Strauss Syndrome
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 14, 2026, 2:00 PM EDT
Withdrawn No phase listed Observational

Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study

NCT03182049
View directory record Official record
Conditions
Granulomatosis With Polyangiitis
Interventions
Airway assessment, Rheumatology assessment
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Sep 14, 2026, 2:00 PM EDT
Terminated Phase 4 Interventional

Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

NCT02626845
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (Wegener's Granulomatosis)
Interventions
Rituximab, Placebo
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 14, 2026, 2:00 PM EDT
Terminated Phase 2 Interventional Results available

PR3-AAV Resilient Remission or PRRR

NCT05376319
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
Interventions
Obinutuzumab, Rituximab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 14, 2026, 2:00 PM EDT
Completed Phase 2 Interventional

Daclizumab to Treat Wegener's Granulomatosis

NCT00040248
View directory record Official record
Conditions
Wegener's Granulomatosis
Interventions
Daclizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 14, 2026, 2:00 PM EDT
Recruiting Phase 2 Interventional

Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

NCT02947945
View directory record Official record
Conditions
Asthma
Interventions
Reslizumab
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 14, 2026, 2:00 PM EDT
Terminated No phase listed Observational

Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study

NCT01586858
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions
Observational
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 100 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Sep 14, 2026, 2:00 PM EDT
Completed No phase listed Observational Results available

An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

NCT01613599
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions
Rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 14, 2026, 2:00 PM EDT
Completed No phase listed Observational

Reproductive Health in Men and Women With Vasculitis

NCT02176070
View directory record Official record
Conditions
Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Sep 14, 2026, 2:00 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

NCT00104299
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
Interventions
Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 14, 2026, 2:00 PM EDT
Completed No phase listed Observational

Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis

NCT00315393
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Wegener's
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
6
States / cities
Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 14, 2026, 2:00 PM EDT
Completed No phase listed Observational

Impact of Vasculitis on Employment and Income

NCT02476292
View directory record Official record
Conditions
Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis, Temporal Arteritis, Wegener Granulomatosis, Henoch-Schoenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa (PAN), Takayasu's Arteritis, Urticarial Vasculitis
Interventions
online questionnaire
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Sep 14, 2026, 2:00 PM EDT
Recruiting No phase listed Observational

One-Time DNA Study for Vasculitis

NCT01241305
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2028
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 14, 2026, 2:00 PM EDT
Recruiting Phase 3 Interventional

Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

NCT07444567
View directory record Official record
Conditions
Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
Interventions
Benralizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Aurora, Colorado • Bethesda, Maryland • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 14, 2026, 2:00 PM EDT